help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crowley, W. F.
Right arrow Articles by Cutler, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crowley, W. F., Jr
Right arrow Articles by Cutler, G. B., Jr

Journal of Clinical Endocrinology & Metabolism, Vol 52, 370-372, Copyright © 1981 by Endocrine Society


ARTICLES

Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty

WF Crowley Jr, F Comite, W Vale, J Rivier, DL Loriaux and GB Cutler Jr

A two year girl with idiopathic true precocious puberty was treated with a long-acting LHRH agonist, D-Trp6-Pro9-NEt-LHRH (LHRHa). Prior to therapy, the patient demonstrated pulsatile gonadotropin secretion during both night and day, a pubertal response to exogenous LHRH, and an elevated plasma estradiol level. After eight weeks of therapy (4 microgram/kg daily), a mean gonadotropin levels fell to the prepubertal range, there was no evidence of pulsatile discharge of gonadotropins nor any response to exogenous LHRH, and plasma estradiol levels became undetectable. No adverse drug reactions were encountered and all effects of therapy were reversed following cessation of treatment for two months. LHRH analogs may offer a new approach to the therapy of idiopathic precocious puberty and merit further study.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo
Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 190 - 195.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. A. Eugster, W. Clarke, G. B. Kletter, P. A. Lee, E. K. Neely, E. O. Reiter, P. Saenger, D. Shulman, L. Silverman, L. Flood, et al.
Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1697 - 1704.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J.-C. Carel, J. Blumberg, C. Seymour, C. Adamsbaum, N. Lahlou, and for the Triptorelin 3-month CPP Study Group
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
Eur. J. Endocrinol., January 1, 2006; 154(1): 119 - 124.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Tanaka, H. Niimi, N. Matsuo, K. Fujieda, K. Tachibana, K. Ohyama, M. Satoh, and K. Kugu
Results of Long-Term Follow-Up after Treatment of Central Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1371 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain
Precocious puberty and statural growth
Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. M. Lee
Is Treatment with a Luteinizing Hormone-Releasing Hormone Agonist Justified in Short Adolescents?
N. Engl. J. Med., March 6, 2003; 348(10): 942 - 945.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. V. MERICQ, M. EGGERS, A. AVILA, G. B. CUTLER Jr., and F. CASSORLA
Near Final Height in Pubertal Growth Hormone (GH)-Deficient Patients Treated with GH Alone or in Combination with Luteinizing Hormone-Releasing Hormone Analog: Results of a Prospective, Randomized Trial
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 569 - 573.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
A. Cassio, E. Cacciari, A. Balsamo, M. Bal, and D. Tassinari
Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
Arch. Dis. Child., October 1, 1999; 81(4): 329 - 332.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
W F Paterson, E McNeill, S Reid, A S Hollman, and M D C Donaldson
Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty
Arch. Dis. Child., October 1, 1998; 79(4): 323 - 327.
[Abstract] [Full Text]


Home page
Reproductive SciencesHome page
A. S. Penzias, S. R. Goodman, G. Rossi, F. N. Shamma, R. F. Aten, H. R. Behrman, and E. E. Jones
Preliminary Evidence That GnRH Has the Properties of a Growth Hormone-Releasing Factor In Vivo in the Rat
Reproductive Sciences, July 1, 1995; 2(4): 623 - 629.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society